Clinical Trials

The FDA accepted an investigational new drug application allowing for the start of a phase 1 trial to evaluate the tolerability of AVB-101 in patients with platinum resistance ovarian cancer.

A phase 1/2 clinical trial examining the combination of afuresertib, sintilimab, and chemotherapy in patients with specific solid tumors who were resistant to anti-PD-1/PD-L1 therapy has dosed its first patient.

The CYAD-101-002 trial may resume after the FDA lifted the partial clinical hold to evaluate risk to study patients with metastatic colorectal cancer.

: On the heels of positive findings from the phase 1/1b AURELIO-03, 1 patient with an advanced/refractory solid tumor has been dosed with SOT101 and pembrolizumab in the follow-up study, AURELIO-04.

Following positive phase 1/2 results of DS-7300 use in patients with extensive-stage small cell lung cancer, a phase 2 study has dosed its first patient with the experimental agent.

Treatment with ITI-3000 has begun in a first-in-human, phase 1 study of patients with Merkel cell carcinoma.

The phase 2 LOTIS-9 study of loncastuximab tesirine-lpyl combined with rituximab has been initiated with the dosing of the first patient with previously untreated diffuse large B-cell lymphoma.

The phase 3 ZILO-301 study will evaluate the combination of zilovertamab and ibrutinib in patients with relapsed or refractory mantle cell lymphoma.

Upcoming data from part C of the DisTinGuish study will further confirm the benefit and safety of DKN-01 in combination with tislelizumab in patients with unresectable, locally advanced or metastatic gastric or gastroesophageal adenocarcinoma.

Remote technology and decentralization tools in cancer clinical trials may be linked to an increase in patient consent rate, according to findings from a cross-sectional study.

Two phase 1/2 trials of IAP0971 and IAE0972 in patients with locally-advanced or metastatic malignant tumors have dosed their first patients.

Leonard Kalman, MD, explains the disparities in clinical trial enrollment, which include access to care, lack of education, and low cancer screening rates.

The recruitment of patients with melanoma has been completed in the phase 2 INITIUM clinical trial. Topline results from the study are expected to be reported in early 2023.

At the Dana-Farber Cancer Institute and Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, clinical trial disruptions were observed early in the pandemic compared with later. Enrollment gradually recovered over time.

A phase 1/1b monotherapy clinical trial of RMC-6236 for the treatment of patients with advanced solid tumors driven by a variety of RAS mutations has dosed its first patient.

Talquetamab is being investigated in a first-in-human study of patients with relapsed or refractory multiple myeloma.

Enrollment has been completed for the phase 3 PRESERVE 1 trial of trilaciclib in patients with metastatic colorectal cancer receiving chemotherapy.

On the heels of positive phase 1 data, the phase 3 TROPION-Breast02 clinical trial has begun dosing of datopotamab deruxtecan in select patients with metastatic triple-negative breast cancer.

Results from JACKPOT8 presented during the 2022 EHA Congress show that golidocitnib has encouraging anti-tumor efficacy and tolerable safety in patients with relapsed or refractory peripheral T-cell lymphoma.

YL-13027 has been dosed for the first time in a patient with advanced solid tumors.

Data from ANTLER presented during the 2022 EHA Congress show initial findings of CB-010 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

Toni K. Choueiri, MD, discusses the design of the phase 3 LITESPARK-022 study, which investigates adjuvant pembrolizumab in patients with clear cell renal cell carcinoma.

Dosing of NX-2127 in patients with chronic lymphocytic leukemia has begun in a phase 1b clinical trial.

The FDA has lifted the partial clinical hold on the phase 1 NEON-2 trial of davoceticept plus pembrolizumab in adult patients with advanced solid tumors or lymphoma.

A new murine monoclonal antibody B43.12 is under investigation in combination with paclitaxel and carboplatin as a treatment option for patients with advanced epithelial ovarian cancer.

Investigators of the phase 1/2 IMAGINE study, evaluating MT-101 in patients with refractory or relapsed peripheral T-cell lymphoma, have dosed its first patient.

The phase 1/2 THETIS clinical trial is actively recruiting patients with metastatic melanoma to be treated with the investigation combination of ATL001 and an immune checkpoint inhibitor.

The phase 2 clinical trial of the combination therapy, GT90001 and nivolumab, for the treatment of patients with advanced hepatocellular carcinoma has dosed its first patient.

Florida Cancer Specialists & Research Institute sites and site worldwide are now recruiting patients for the PROPHETIC study.

As a follow-up to the success observed in the phase 2 COAST study, investigators of the phase 3 PACIFIC-9 have begun administering durvalumab in combination with monalizumab or oleclumab to patients with unresectable, stage III non–small cell lung cancer.